Show simple item record

dc.contributor.authorSzabo, Gyongyi
dc.contributor.authorKodys, Karen
dc.contributor.authorMiller-Graziano, Carol L.
dc.date2022-08-11T08:08:37.000
dc.date.accessioned2022-08-23T16:01:14Z
dc.date.available2022-08-23T16:01:14Z
dc.date.issued1991-11-01
dc.date.submitted2010-04-21
dc.identifier.citationJ Clin Immunol. 1991 Nov;11(6):336-44.
dc.identifier.issn0271-9142 (Linking)
dc.identifier.pmid1761639
dc.identifier.urihttp://hdl.handle.net/20.500.14038/31073
dc.description.abstractAberrant monocyte mediator production is pivotal in the development of posttrauma immunosuppression. We have previously shown that immunodepressed trauma patients' monocytes produce elevated interleukin-6, suggesting their in vivo preactivation. This study confirms that preactivated patients' Mo produce greater levels of IL-6 than normals' Mo to the same in the in vitro Fc gamma RI stimulation. We also demonstrate the capacity of interleukin-4 to downregulate the elevated interleukin-6 production of trauma patients' in vivo preactivated monocytes. Monocyte interleukin-6 downregulation by interleukin-4 is dose dependent and occurs whether Fc gamma RI cross-linking, muramyl dipeptide, indomethacin plus muramyl dipeptide, or interferon-gamma plus muramyl dipeptide is the interleukin-6 inducing stimulus. Furthermore, interleukin-4-dependent downregulation of monocyte interleukin-6 expression is confirmed at both the supernatant and the mRNA levels. Simultaneous downregulation of posttrauma elevated monokines implies a possible therapeutic benefit of interleukin-4 for trauma patients.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=1761639&dopt=Abstract">Link to Article in PubMed</a>
dc.relation.urlhttp://dx.doi.org/10.1007/BF00918799
dc.subjectAdult
dc.subjectAged
dc.subjectBurns
dc.subjectDinoprostone
dc.subjectDown-Regulation
dc.subjectFemale
dc.subjectHumans
dc.subjectImmune Tolerance
dc.subjectInterleukin-4
dc.subjectInterleukin-6
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectMonocytes
dc.subjectRNA, Messenger
dc.subjectTumor Necrosis Factor-alpha
dc.subjectWounds and Injuries
dc.subjectDigestive System Diseases
dc.subjectGastroenterology
dc.titleElevated monocyte interleukin-6 (IL-6) production in immunosppressed trauma patients. II. Downregulation by IL-4
dc.typeJournal Article
dc.source.journaltitleJournal of clinical immunology
dc.source.volume11
dc.source.issue6
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/gastroenterology_pp/13
dc.identifier.contextkey1282306
html.description.abstract<p>Aberrant monocyte mediator production is pivotal in the development of posttrauma immunosuppression. We have previously shown that immunodepressed trauma patients' monocytes produce elevated interleukin-6, suggesting their in vivo preactivation. This study confirms that preactivated patients' Mo produce greater levels of IL-6 than normals' Mo to the same in the in vitro Fc gamma RI stimulation. We also demonstrate the capacity of interleukin-4 to downregulate the elevated interleukin-6 production of trauma patients' in vivo preactivated monocytes. Monocyte interleukin-6 downregulation by interleukin-4 is dose dependent and occurs whether Fc gamma RI cross-linking, muramyl dipeptide, indomethacin plus muramyl dipeptide, or interferon-gamma plus muramyl dipeptide is the interleukin-6 inducing stimulus. Furthermore, interleukin-4-dependent downregulation of monocyte interleukin-6 expression is confirmed at both the supernatant and the mRNA levels. Simultaneous downregulation of posttrauma elevated monokines implies a possible therapeutic benefit of interleukin-4 for trauma patients.</p>
dc.identifier.submissionpathgastroenterology_pp/13
dc.contributor.departmentDepartment of Medicine, Division of Gastroenterology
dc.contributor.departmentDepartment of Surgery
dc.source.pages336-44


This item appears in the following Collection(s)

Show simple item record